

# Financial Tear Sheet

## Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

## Transfer Agent

### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(http://www.computershare.com)

## Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

## Stock Performance: CTIC (Nasdaq)

**Exchange** NASDAQ CM (US Dollar)

**Price** **\$4.18**

**Change (%)** ▲ 0.01 (0.24%)

**Volume** 14,365

**52 Week Low** \$3.07

**Market Cap** \$117,938,060

**Rolling EPS** -2.53

**PE Ratio** 0

**Shares Outstanding** 28,214,847

Data as of 05/26/17 4:00 p.m. ET



## Recent Headlines & Events

May 03, 2017 - 4:02 p.m.

CTI BioPharma Reports First Quarter 2017  
Financial Results

([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2269415](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2269415))

Apr 26, 2017 - 4:07 p.m.

CTI BioPharma to Report First Quarter  
2017 Financial Results on May 3, 2017

([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2266029](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2266029))

Apr 25, 2017 - 1:30 a.m.

Servier and CTI BioPharma Expand  
License and Collaboration Agreement to  
Develop and Commercialize PIXUVRI®

([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2264222](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2264222))

There are currently no events scheduled.

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	74	44.72	37.1	10,474,311
Mutual Fund	20	4.08	3.4	960,426
Insider *	11	24.27	17.6	4,969,236

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	4,479,691	15.9	-3	03/31/17
Baxalta, Inc.	1,567,398	5.6	0	01/01/17
NB Public Equity Komplementar ApS	1,356,635	4.8	90,000	12/31/16
The Vanguard Group, Inc.	812,498	2.9	53,343	03/31/17
BlackRock Institutional Trust Company, N.A.	352,059	1.3	842	03/31/17
Bianco (James A)	178,013	0.6	-50,054	02/10/17
Millennium Management LLC	159,120	0.6	114,070	03/31/17
Renaissance Technologies LLC	119,345	0.4	-54,704	03/31/17
Geode Capital Management, L.L.C.	117,520	0.4	520	03/31/17
Singer (Jack W)	99,405	0.4	-29,687	02/10/17

*Data provided by Nasdaq. Minimum 15 minutes delayed.*